TradingKey

Mais detalhes de Vyne Therapeutics Inc Empresa

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Informações da empresa

Código da empresaVYNE

Nome da EmpresaVyne Therapeutics Inc

Data de listagemJan 25, 2018

CEOMr. David Domzalski

Número de funcionários13

Tipo de títulosOrdinary Share

Fim do ano fiscalJan 25

Endereço685 Route 202/206 N., Suite 301

CidadeBRIDGEWATER

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal08807

Telefone18007757936

Sitehttps://vynetherapeutics.com/

Código da empresaVYNE

Data de listagemJan 25, 2018

CEOMr. David Domzalski

Executivos da empresa

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

116.19K

-2.86%

Mr. Patrick G. Lepore

Lead Independent Director

51.47K

--

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

42.30K

-5.45%

Mr. Steven L. Basta

Independent Director

7.45K

--

Mr. Anthony Bruno

Independent Director

--

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

--

Ms. Sharon Barbari

Independent Director

--

Dr. Christine Borowski, Ph.D.

Independent Director

--

Mr. David Domzalski

President, Chief Executive Officer, Director

--

Ms. Elisabeth A. Sandoval Little

Independent Director

--

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

116.19K

-2.86%

Mr. Patrick G. Lepore

Lead Independent Director

51.47K

--

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

42.30K

-5.45%

Mr. Steven L. Basta

Independent Director

7.45K

--

Mr. Anthony Bruno

Independent Director

--

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

--

Detalhamento da receita

Moeda: USDAtualizado em: dom, 6 de jul

FY2024

FY2023

FY2022

FY2021

FY2020

Por EmpresaUSD

Nome

Receita

Proporção

Royalty revenues

501.00K

0.00%

Sem dados

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Royalty revenues

501.00K

0.00%

Distribuição de ações

Atualizado em: dom, 1 de jun

Investidores

Tipos de investidores

Investidores

Proporção

Eventide Asset Management, LLC

8.37%

Access Industries, Inc.

6.70%

Citadel Advisors LLC

6.60%

Acorn Capital Advisors, LLC

4.72%

Delaware Street Capital, L.L.C.

4.18%

Other

69.43%

Investidores

Proporção

Eventide Asset Management, LLC

8.37%

Access Industries, Inc.

6.70%

Citadel Advisors LLC

6.60%

Acorn Capital Advisors, LLC

4.72%

Delaware Street Capital, L.L.C.

4.18%

Other

69.43%

Tipos de investidores

Investidores

Proporção

Hedge Fund

26.69%

Investment Advisor

17.90%

Corporation

6.70%

Individual Investor

2.22%

Private Equity

1.54%

Investment Advisor/Hedge Fund

1.05%

Research Firm

0.32%

Venture Capital

0.20%

Other

43.37%

Participação acionária institucional

Atualizado em: ter, 1 de jul

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q2

83

9.44M

56.62%

-1.32M

2025Q1

81

9.36M

56.20%

-1.38M

2024Q4

92

9.37M

63.49%

-533.87K

2024Q3

88

8.98M

61.30%

-594.32K

2024Q2

89

9.65M

66.73%

+287.65K

2024Q1

92

9.64M

67.66%

+101.95K

2023Q4

101

10.22M

72.71%

+4.63M

2023Q3

117

471.27K

14.37%

-340.06K

2023Q2

135

501.83K

15.37%

-314.68K

2023Q1

168

461.83K

16.95%

-412.21K

Ver Mais

Atividade dos acionistas

Nome

Ações detidas

Proporção

Variação

Var. %

Data

Eventide Asset Management, LLC

1.39M

8.37%

--

Mar 31, 2025

Access Industries, Inc.

1.12M

6.7%

--

Feb 14, 2025

Citadel Advisors LLC

1.10M

6.6%

-130.13K

-10.58%

Mar 31, 2025

Acorn Capital Advisors, LLC

785.94K

4.72%

+328.97K

+71.99%

Mar 31, 2025

Delaware Street Capital, L.L.C.

696.47K

4.18%

--

Sep 30, 2024

Dafna Capital Management, LLC

636.10K

3.82%

+636.10K

--

Mar 31, 2025

The Vanguard Group, Inc.

475.65K

2.85%

+521.00

+0.11%

Mar 31, 2025

Exome Asset Management LLC

462.80K

2.78%

+109.37K

+30.94%

Mar 31, 2025

Palo Alto Investors LP

445.43K

2.67%

--

Mar 31, 2025

Adage Capital Management, L.P.

344.13K

2.06%

+190.00K

+123.27%

Mar 31, 2025

Ver Mais

ETFs Relacionados

Atualizado em: sáb, 2 de ago

Nome

Proporção

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Proporção0%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações

Data

Tipo

Proporção

Feb 10, 2023

Merger

18<1

Feb 10, 2023

Merger

18<1

Feb 10, 2023

Merger

18<1

Feb 10, 2023

Merger

18<1

Feb 12, 2021

Merger

4<1

Feb 12, 2021

Merger

4<1

Data

Tipo

Proporção

Feb 10, 2023

Merger

18<1

Feb 10, 2023

Merger

18<1

Feb 10, 2023

Merger

18<1

Feb 10, 2023

Merger

18<1

Feb 12, 2021

Merger

4<1

Feb 12, 2021

Merger

4<1

Feb 12, 2021

Merger

4<1

Feb 12, 2021

Merger

4<1

Vyne Therapeutics Inc

0.365USD

Vyne Therapeutics Inc

0.365

Visão Geral

Empresa

Serviços Financeiros